MDxHealth SA (NASDAQ:MDXH) Short Interest Down 68.8% in June

MDxHealth SA (NASDAQ:MDXH) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 33,040 shares, a drop of 68.8% from the June 15th total of 106,013 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 911,575 shares, the days-to-cover ratio is currently 0.0 days.

MDxHealth Stock Performance

Shares of MDXH stock traded down $0.01 on Friday, hitting $0.48. 463,087 shares of the stock traded hands, compared to its average volume of 737,024. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33. The firm’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $2.32. The stock has a market capitalization of $23.56 million, a PE ratio of -0.73 and a beta of 1.43.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. On average, equities research analysts anticipate that MDxHealth will post -0.6 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on MDXH. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. William Blair lowered MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Lake Street Capital reduced their price target on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, May 14th. TD Cowen reiterated a “buy” rating and set a $1.50 target price (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. Finally, BTIG Research lowered their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.62.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently modified their holdings of MDXH. Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the third quarter worth about $53,000. Russell Investments Group Ltd. acquired a new stake in MDxHealth in the third quarter valued at approximately $461,000. Kennedy Capital Management LLC acquired a new stake in MDxHealth in the third quarter valued at approximately $1,826,000. FreeGulliver LLC lifted its stake in MDxHealth by 104.7% in the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after acquiring an additional 129,348 shares during the last quarter. Finally, Panoramic Capital LLC acquired a new position in MDxHealth during the 3rd quarter worth approximately $721,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.